Louvain-La-Neuve, Belgium, 09 July 2019 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed a contract and received the first payment for a Proteus®ONE solution with The University of Kansas Health System. The contract includes a plan for a possible extension with a second Proteus®One unit in the future. The proton therapy center will be built at the Main Campus of The University of Kansas Health System in Kansas City, Kansas. Construction is anticipated to begin later this year.

The contract includes a long-term operation and maintenance agreement and the typical end-user price for a Proteus®ONE* solution with a maintenance contract is between EUR 35 and 40 million. IBA will begin to recognize revenue for the contract in the 2019 financial year.

Olivier Legrain, Chief Executive Officer of IBA, commented: "We are delighted to collaborate with The University of Kansas Health System, one of the leading academic medical centers in the US. With a current market share of around 50% in compact proton therapy systems, IBA's Proteus®ONE solution clearly stands out as the most advanced technology available in the market. In addition, our current research projects aiming at delivering Spot Scanning Proton Arc therapy as well as FLASH therapy dose rates in the near future will keep us ahead of our competitors for the years to come."


Bob Page, President and chief executive officer of The University of Kansas Health System commented: "We are excited to partner with IBA, the world's leading proton therapy system provider, to bring proton therapy to Kansas City and the region. IBA's Proteus® ONE represents one of the most advanced solutions to delivering proton therapy. With the first system in place, and the ability to add a second system in the future, patients will be able to stay closer to home to receive the most advanced cancer care available.


About Proteus®ONE
Proteus®ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. Proteus®ONE is smaller, more affordable, easier to install and to operate, making this advanced radiation therapy modality available to more institutions and patients worldwide.

* Proteus®ONE is the brand name of Proteus®235.


About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1400 people worldwide, IBA has installed systems across the world.

Back to HCB News

Rad Oncology Homepage